2024
Sorafenib or anthracycline‐based chemotherapy for progressive desmoid tumors
Costa P, Arora A, Fernandez Y, Yi I, Bakkila B, Tan H, Coelho P, Campoverde L, Hardy N, Bialick S, Freire A, D’Amato G, Chang Y, Mesenger J, Subhawong T, Haims A, Hurwitz M, Olino K, Turaga K, Deshpande H, Trent J. Sorafenib or anthracycline‐based chemotherapy for progressive desmoid tumors. Cancer 2024, 131: e35647. PMID: 39543805, DOI: 10.1002/cncr.35647.Peer-Reviewed Original ResearchProgression-free survivalAnthracycline-containing regimensAnthracycline-based therapyDesmoid tumorsAdverse eventsOne-year progression-free survivalMulti-institutional retrospective analysisAnthracycline-containing regimenCommon grade 1Desmoid tumor patientsGrade 3 eventsAnthracycline-based chemotherapyHand-foot syndromeSecondary end pointsActivity of sorafenibProgressive desmoid tumorsYear of treatmentMedian TTRBaseline characteristicsTumor patientsLocal invasionTreatment responseSorafenibAnthracyclinesEnd pointsOnset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 study
Loggers E, Chugh R, Federman N, Hartner L, Riedel R, Cho S, Hyslop D, Lim A, Oton A, Oktay K. Onset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 study. Cancer 2024, 130: 2812-2821. PMID: 38703010, DOI: 10.1002/cncr.35324.Peer-Reviewed Original ResearchFemales of reproductive potentialFollicle-stimulating hormoneReturn of menstruationOvarian toxicityDesmoid tumorsFollow-upContinuous 28-day cyclesLost to follow-upPhase 3 studyProgressive desmoid tumorsPost hoc analysisSafety populationNirogacestatStopping treatmentHormone valuesSafety signalsHoc analysisPatientsPerimenopausal symptomsMenstruationGamma-secretase inhibitorsPlaceboRandom femalesTumorEvent follow-up
2022
Neurogenic orthostatic hypotension after treatment with sorafenib
Wippel C, Deshpande H, Patwa H, Peixoto A. Neurogenic orthostatic hypotension after treatment with sorafenib. BMJ Case Reports 2022, 15: e247140. PMID: 36549761, PMCID: PMC9791444, DOI: 10.1136/bcr-2021-247140.Peer-Reviewed Original ResearchConceptsOrthostatic hypotensionVascular endothelial growth factor inhibitorsLower extremity weaknessNeurogenic orthostatic hypotensionPalpable abdominal massGrowth factor inhibitorsHistory of fatigueAppropriate chronotropic responseSupine hypertensionAbdominal painAutonomic testingExtremity weaknessAbdominal massSodium intakeChronotropic responseFactor inhibitorsCompression stockingsDesmoid tumorsLiberal fluidsSympathetic responseHypotensionTumor growthSorafenibGradual improvementTreatment
2018
Phase III, randomized, double blind, placebo-controlled trial of sorafenib in desmoid tumors (Alliance A091105).
Gounder M, Mahoney M, Van Tine B, Ravi V, Attia S, Deshpande H, Gupta A, Milhem M, Conry R, Movva S, Pishvaian M, Crawford J, Sabagh T, Maki R, Tap W, Lefkowitz R, Agaram N, Wright J, Dueck A, Schwartz G. Phase III, randomized, double blind, placebo-controlled trial of sorafenib in desmoid tumors (Alliance A091105). Journal Of Clinical Oncology 2018, 36: 11500-11500. DOI: 10.1200/jco.2018.36.15_suppl.11500.Peer-Reviewed Original Research
2012
Management and Recurrence Patterns of Desmoids Tumors: A Multi-institutional Analysis of 211 Patients
Peng PD, Hyder O, Mavros MN, Turley R, Groeschl R, Firoozmand A, Lidsky M, Herman JM, Choti M, Ahuja N, Anders R, Blazer DG, Gamblin TC, Pawlik TM. Management and Recurrence Patterns of Desmoids Tumors: A Multi-institutional Analysis of 211 Patients. Annals Of Surgical Oncology 2012, 19: 4036-4042. PMID: 22972507, PMCID: PMC3568525, DOI: 10.1245/s10434-012-2634-6.Peer-Reviewed Original ResearchConceptsRecurrence-free survivalDesmoid tumorsTumor locationWorse recurrence-free survivalRare soft tissue neoplasmMajor surgical centersR0 surgical marginsDisease-free survivalEffective adjuvant therapyManagement of patientsPredictors of recurrenceRate of recurrenceMulti-institutional analysisSoft tissue neoplasmBackgroundDesmoid tumorsResultsMedian ageAdjuvant therapyMost patientsSurgical resectionMargin statusSurgical marginsSurgical centersTreatment characteristicsRecurrence patternsAbdominal cavity
2009
Desmoid tumor in the pediatric population: a report of two cases
Ramirez R, Otsuka N, Apel D, Bowen R. Desmoid tumor in the pediatric population: a report of two cases. Journal Of Pediatric Orthopaedics B 2009, 18: 141-144. PMID: 19322113, DOI: 10.1097/bpb.0b013e3283298923.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply